Tacedinaline

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameTacedinaline
Drug Alias Name他地那兰Ac-Din泰克地那林Acetyldinalinetacedinalinum +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsLung NeoplasmsPancreatic NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesParke-Davis GmbhPfizer IncH Lee Moffitt Cancer Center & Research Institute
Active IndicationsN/A
Inactive IndicationsLung NeoplasmsPancreatic NeoplasmsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksKEGG